Burning Rock Q2 Revenue Falls 9%; In-Hospital Business Posts Growth
Burning Rock Biotech (BNR) reported Q2 2026 revenue of RMB134.8M, down 9% YoY. In-hospital business revenue grew to RMB67.1M, while central lab and pharma R&D services declined. Gross profit was RMB97.8M, with a gross margin of 72.6%. Net loss was RMB18.4M. The company expects regulatory progress and new product approvals to drive long-term growth. BNR stock is currently at $12.17, up 1.49%.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term selling, but ongoing regulatory submissions and a shift to higher‑margin in‑hospital testing could mitigate longer‑term downside.
Market read
First‑time Q2 earnings disclosure for a small‑cap biotech; relevant for traders tracking Chinese biotech earnings and regulatory pipelines.
What to watch
Cash balance of RMB419 million provides runway; in‑hospital growth may accelerate later in the year.
Background
Burning Rock Biotech Limited (BNR) released its Q2 2026 earnings, showing a revenue decline and higher net loss while reporting progress on product regulatory reviews.
Ticker impact
Q2 2026 revenue fell 9% YoY to RMB134.8 million and net loss widened to RMB18.4 million.
Potential downside of 5‑8% over the next few days.
Revenue decline and widening loss signal slower growth; however, in‑hospital revenue growth and regulatory progress could limit the drop.
Market effects
Highlights pressure on Chinese precision‑oncology and NGS service providers.
May weigh on other China‑listed biotech stocks reporting Q2 results.
Limited; primarily a regional biotech story.
Counterpoint
Regulatory approvals in the pipeline could offset the revenue dip and support a rebound.
Key entities
- companyBurning Rock Biotech Limited
Precision oncology firm listed on NASDAQ under ticker BNR.
